Radiol Oncol 2023; 57(1): 111-120. doi: 10.2478/raon-2023-0003 111 research article Association of OPRM1, MIR23B, and MIR107 genetic variability with acute pain, chronic pain and adverse effects after postoperative tramadol and paracetamol treatment in breast cancer Zala Vidic1, Katja Goricar1, Branka Strazisar2, Nikola Besic2, Vita Dolzan1 1 Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia 2 Institute of Oncology, Ljubljana, Slovenia Radiol Oncol 2023; 57(1): 111-120. Received 14 September 2022 Accepted 28 September 2022 Correspondence to: Prof. Vita Dolžan, M.D., Ph.D., Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia. E-mail: vita.dolzan@mf.uni-lj.si Disclosure: No potential conflicts of interest were disclosed. This is an open access article distributed under the terms of the CC-BY license (https://creativecommons.org/licenses/by/4.0/). Background. Tramadol is an opioid analgesic often used for pain management after breast cancer surgery. Its anal- gesic activity is due to the activation of the μ-opioid receptor, encoded by the OPRM1 gene. This study investigated the association of genetic variability in OPRM1 and its regulatory miRNA genes with outcomes of tramadol/paraceta- mol treatment after breast cancer surgery with axillary lymphadenectomy. Patients and methods. The study included 113 breast cancer patients after breast cancer surgery with axillary lymphadenectomy treated with either 75/650 mg or 37.5/325 mg of tramadol with paracetamol for pain relief within the randomized clinical trial KCT 04/2015-DORETAonko/si at the Institute of Oncology Ljubljana. All patients were geno- typed for OPRM1 rs1799971 and rs677830, MIR23B rs1011784, and MIR107 rs2296616 using competitive allele-specific PCR. The association of genetic factors with acute and chronic pain as well as adverse effects of tramadol treatment was evaluated using logistic regression, Fisher’s exact test, and Mann-Whitney test. Results. The investigated OPRM1 related polymorphisms were not associated with acute pain assessed with the VAS scale within four weeks after surgery (all P > 0.05). Carriers of at least one polymorphic OPRM1 rs1799971 allele had a higher risk of constipation in the first four weeks after surgery compared to non-carriers (OR = 4.5, 95% CI = 1.6–12.64, P = 0.004). Carriers of at least one polymorphic OPRM1 rs677830 allele had a higher risk of constipation after third week of tramadol treatment (OR = 3.11, 95% CI = 1.08–8.89, P = 0.035). Furthermore, carriers of two polymorphic MIR23B rs1011784 alleles had a higher risk of nausea after 28 days of tramadol treatment (OR = 7.35, 95% CI = 1.27–42.6, P = 0.026), while heterozygotes for MIR107 rs2296616 allele had a lower risk of nausea after 21 days of tramadol treatment (OR = 0.21, 95% CI = 0.05–0.87, P = 0.031). In carriers of two polymorphic MIR107 rs2296616 alleles, chronic pain was significantly more common than in carriers of two wild-type alleles (P = 0.004). Carriers of at least one polymorphic MIR23B rs1011784 allele experienced more neuropathic pain after adjustment for tramadol dose (OR = 2.85, 95% CI = 1.07–7.59, P = 0.036), while carriers of at least one polymorphic OPRM1 rs677830 allele experienced less neuropathic pain compared to carriers of two wild-type alleles (OR = 0.38, 95% CI = 0.15–0.99, P = 0.047). Conclusions. Genetic variability of OPRM1 and genes coding for miRNAs that could affect OPRM1 expression may be associated with adverse effects of tramadol/paracetamol treatment as well as with chronic and neuropathic pain after breast cancer surgery with axillary lymphadenectomy. Key words: breast cancer surgery; miRNA; OPRM1; pain treatment; tramadol Radiol Oncol 2023; 57(1): 111-120. Vidic Z et al. / OPRM1 related genetic variability and postoperative pain treatment in breast cancer112 Introduction Tramadol is a synthetic centrally acting opioid drug that exhibits its analgesic activity by bind- ing to μ-opioid receptor (MOR).1 It is widely used for the treatment of moderate to severe acute pain after breast cancer surgery with axillary lymphad- enectomy.2 Tramadol is considered a relatively safe opioid drug since it does not cause respiratory de- pression at therapeutic doses and is less likely to cause addiction compared to many other opioids. However, its analgesic efficiency is lesser com- pared to morphine.1-3 MORs, encoded by the OPRM1 gene, are mem- bers of the Rhodopsin family of G-protein coupled receptors.4 MORs are expressed in the cerebral cortex, thalamus, periaqueductal gray, nucleus accumbens, and basolateral amygdala, and are therefore responsible for the occurrence of eu- phoria, dependence, respiratory depression, and activation of the reward system.5 They are crucial for the analgesic effects of the majority of opioid drugs.6 It has been shown that polymorphisms in the OPRM1 gene can affect the efficacy of analgesic ac- tion of several opioid drugs. One of the most stud- ied single nucleotide polymorphisms (SNPs) of the OPRM1 gene is rs1799971 (c.118A>G; p.Asn40Asp).4 A study performed in European subjects on long- term treatment for chronic pain with different opioids, including tramadol, reported a higher frequency of adverse effects in wild-type sub- jects compared to individuals with the AG or GG genotype.7 A study in Chinese population showed greater analgesic action of tramadol combined with paracetamol (acetaminophen) for the treat- ment of peripheral neuropathy in wild-type pa- tients compared to carriers of polymorphic G al- lele.8 Numerous studies focused on investigating the impact of this SNP on response to morphine treatment in different populations. Many of them confirmed the association between rs1799971 and pain relief or morphine dose requirements.9-12 Furthermore, a haplotype of seven OPRM1 SNPs, that included rs1799971 and another non-synony- mous SNP, rs677830 (c.1231C>T, p.Gln411Ter) was associated with postoperative morphine response in Caucasians.12 OPRM1 gene expression may be regulated by non-coding RNAs such as microRNAs (miRNAs) that bind to target mRNAs molecules and prevent protein translation or promote mRNA degrada- tion.13,14 It was shown that several miRNAs can af- fect MOR expression, or lead to opioid dependence or tolerance.15,16,17 Furthermore, opioids can regu- late the expression of several miRNAs.15 miRNA-23b was the first identified miRNA molecule that regulates OPRM1 expression17, how- ever miRNA-107 was shown to influence OPRM1 expression as well.15 Both miR-23b and miR107 were experimentally proven to reduce the expres- sion level of OPRM1 splice variants in mouse or human neuronal cell lines, human transfected em- bryonic kidney cell lines, or mouse animal models. The binding of these miRNAs to 3’ UTR of OPRM1 mRNAs prevented them from binding to ribo- somes without altering the respective mRNAs lev- els. Furthermore, these studies also reported that long-term morphine treatment increased miRNAs expression.15,17,18 The aim of this study was to evaluate the asso- ciation of OPRM1 rs1799971 and rs677830, MIR23B 1011784, and MIR107 rs2296616 polymorphisms with the severity of acute pain and the presence of adverse effects in the first four weeks after breast cancer surgery with axillary lymphadenectomy as well as with chronic and neuropathic pain at one year after surgery. Patients and methods Patients Our study included breast cancer patients that participated in a prospective double-blind- ed randomized clinical trial at the Institute of Oncology Ljubljana from 2015 to 2018 (Trial KCT 04/2015-DORETAonko/si).2,19 Written informed consent was obtained from all the patients before the inclusion in the clinical trial. The study was approved by the Institutional Review Board of the Institute of Oncology Ljubljana and by The National Medical Ethics Committee of the Republic of Slovenia (Approval number 32/03/15). The main inclusion criteria was treatment with tramadol and paracetamol after breast cancer surgery with axillary lymphadenectomy, while exclusion criteria were: concomitant breast re- construction with a tissue expander or free-flap, hypersensitivity to the drugs used in the study, male gender, pregnancy, high risk of anesthesia according to the criteria of the American Society of Anaesthesiology (ASA over 3), patient’s age under 18 and over 70 years, severe liver or kidney dis- ease, regular use of analgesics or antidepressants, history of opioid abuse or presence of psychiatric illness, such as dementia, schizophrenia, or manic depressive illness. Radiol Oncol 2023; 57(1): 111-120. Vidic Z et al. / OPRM1 related genetic variability and postoperative pain treatment in breast cancer 113 Before the surgery, all patients were examined according to the standard protocol of the Institute of Oncology Ljubljana. Data was collected about the body characteristics, associated diseases or al- lergies, the presence of pain, the use of other medi- cations, and the anaesthesia risk was assessed ac- cording to the criteria of the American Society of Anaesthesiology.20 During surgery, patients received standard postoperative local analgesia. On the first post- operative day, all patients received 37.5/325 mg of tramadol with paracetamol every 8 h, 550 mg of naproxen sodium every 12 h, and 10 mg of meto- clopramide every 8 h. From the second to the 29th postoperative day inclusive, tramadol and par- acetamol dose depended on the group into which a patient was randomized at inclusion in the study. The group with lower analgesia received 37.5/325 mg of tramadol with paracetamol every 8 hours, while the group with higher analgesia received 75/650 mg every 8 hours. The tramadol and par- acetamol doses for each patient were unblinded 15 months after the inclusion of the last patient. For four weeks, all patients also received 550 mg of naproxen sodium twice a day and 20 mg of pan- toprazole once a day. In the case of severe pain de- spite taking tramadol/paracetamol and naproxen sodium, patients received 500 mg of metamizole up to 4 g per day. In the first four weeks after surgery, patients re- corded the severity of the acute pain in the area of the breast and shoulder using the standard visual analog scale (VAS) three times a day. Every day, patients recorded the consumption of medications and the frequency of shoulder exercises. Patients also recorded adverse effects and reported the col- lected data to the healthcare professionals every seven days when they came for the weekly check- ups at the outpatients’ clinic. Before surgery, and again at the final follow-up examination at 12 to 15 months after the surgery, the patients filled in the standardized question- naire of the Institute of Oncology on the presence of chronic pain and the DN4 questionnaire on the presence of neuropathic pain. Methods Bioinformatics analysis First, we searched for potentially functional SNPs in the OPRM1 gene by performing a literature search in PubMed (https://pubmed.ncbi.nlm.nih. gov/), Scholar (https://scholar.google.com/), and SNPedia (https://www.snpedia.com).21 Their mi- nor allele frequency (MAF) was obtained from the dbSNP database from The National Center for Biotechnology Information (NCBI) (https://www. ncbi.nlm.nih.gov/snp/) and linkage disequilib- rium between polymorphisms was evaluated by the LDlink Tool (https://analysistools.cancer.gov/ LDlink/?tab=ldmatrix).22 We identified four mis- sense or nonsense SNPs in the coding regions of the OPRM1 gene with potential function in trama- dol treatment outcome. Among them, only three met the MAF criteria of at least 5% in Caucasians: rs1799971, rs677830 and rs540825. As OPRM1 rs540825 and rs677830 were in high linkage dise- quilibrium (R2 = 0.98), only rs1799971 and rs677830 were included in our study. Next, we searched PubMed, Scholar, and SNPedia for miRNAs with experimentally proven impact on MOR expression or activity. Moreover, we searched the following online databases that can predict the targets of miRNAs or report known associations between a specific gene and miRNA molecules: miRTarBase (http://mirtarbase.cuhk. edu.cn/php/index.php)23, miRDB (http://www. mirdb.org)24, and online tool miRNet (https://www. mirnet.ca)25, to identify miRNAs that can regulate OPRM1. After narrowing down the list of potential miRNAs with impact on MOR function, we iden- tified polymorphisms in genes coding for selected miRNAs with MAF of at least 5% in Caucasians. After the literature search for established roles of these polymorphisms in the expression of OPRM1 or other genes we have selected two polymor- phisms in two miRNA genes for the analysis. In total, four polymorphisms in three genes were selected for inclusion in our study: OPRM1 rs1799971 (NP_000905.3: p.Asn40Asp), OPRM1 rs677830 (NP_001138758.1: p.Gln411Ter), MIR23B rs1011784 (NR_029664.1: n.525G>C), and MIR107 rs2296616 (NR_029524.1: n.-382C>T). Molecular analysis DNA samples were isolated from peripheral blood samples using Qiagen FlexiGene Kit (Qiagen, Hilden, Germany) according to the manufac- turer’s instructions. Genotyping of selected poly- morphisms was performed retrospectively using custom made validated competitive allele-specific polymerase chain reaction (KASP) assays follow- ing the instructions of the manufacturer (LGC Biosearch Technologies, UK). The analysis was repeated for 10% of samples and the results were concordant. Radiol Oncol 2023; 57(1): 111-120. Vidic Z et al. / OPRM1 related genetic variability and postoperative pain treatment in breast cancer114 Statistical analysis Statistical analysis was performed using IBM SPSS v27.0 (IBM Corporation, Armonk, NY, USA). Continuous data were presented with median and interquartile range, while categorical data were presented with frequencies. For each polymor- phism, a standard χ2-test was used to evaluate whether genotype distribution followed Hardy- Weinberg equilibrium (HWE). Only the dominant genetic model was used in all statistical analyses for OPRM1 polymorphisms due to the small num- bers of carriers of two polymorphic alleles, while both dominant and additive genetic model was used in the analyses for polymorphisms in miRNA genes. The association of genetic factors with ad- verse effects, chronic and neuropathic pain was evaluated using binary logistic regression to obtain odds ratios (OR) with corresponding 95-% confi- dence intervals (95% CI). Fisher’s exact test was used if there were no subjects within one of the groups. Mann-Whitney test was used to evaluate the association of polymorphisms with the severity of acute pain. All tests were two-sided and the level of statistical significance was set at 0.05. Results In total, 113 patients were included in the study, 55 (48.7%) received stronger postoperative analgesia and 58 (51.3%) received weaker postoperative an- algesia. Patients’ clinical characteristics are shown in Table 1. Among all patients, 14 (12.4%) patients discontinued tramadol treatment due to severe ad- verse events before the end of four weeks. Adverse TABLE 1. Patients’ clinical characteristics All subjects Stronger postoperative analgesia with tramadol/ paracetamol Weaker postoperative analgesia with tramadol/ paracetamol Sample size N = 113 N = 55 N = 58 Characteristic N (%) N (%) N (%) Age (years) Median (25–75 %) 55 (48–63) 57 (49–64) 53,5 (47.8–61) Weight (kg) Median (25–75 %) 72 (63.5–82) 72 (64–82) 72 (63–82.3) Body Mass Index (kg/m2) Median (25–75 %) 27.1 (23.4–31.0) 26.7 (23.0–30.8) 27.6 (23.5–31.2) Smoking No 87 (77.7) [1] 41 (75.9) [1] 46 (79.3) Yes 25 (22.3) 13 (24.1) 12 (20.7) ASA score 1 22 (19.6) [1] 10 (18.2) 12 (21.1) [1] 2 81 (72.3) 39 (70.9) 42 (73.7) 3 9 (8.0) 6 (10.9) 3 (5.3) Side of the operation Left 62 (54.9) 30 (54.5) 32 (55.2) Right 50 (44.2) 24 (43.6) 26 (44.8) Bilateral 1 (0.9) 1 (1.8) 0 (0.0) Tumor grade 1 4 (3.6) [1] 1 (1.9) [1] 3 (5.2) 1–2 3 (2.7) 2 (3.7) 1 (1.7) 2 39 (34.8) 17 (31.5) 22 (37.9) 2–3 8 (7.1) 2 (3.7) 6 (10.3) 3 58 (51.3) 32 (59.3) 26 (44.8) VAS after 7 days Median (25–75 %) 2 (1–3) [5] 1.3 (1–2) [3] 2 (1–3) [2] VAS after 14 days Median (25–75 %) 1.5 (0–2) [11] 1 (0–2) [9] 2 (1–2) [2] VAS after 21 days Median (25–75 %) 1 (0.4–2) [11] 1 (0–2) [9] 1 (1–2) [2] VAS after 28 days Median (25–75 %) 1 (0–2) [14] 1 (0–1) [10] 1 (1–2) [4] ASA = American Society of Anaesthesiology; N = sample size; [n] = number of missing data; VAS = visual analog scale Genotype frequencies, MAF, and Hardy-Weinberg equilibrium analysis (PHWE) of investigated polymorphisms in all patients enrolled in our study are presented in Table 2. Radiol Oncol 2023; 57(1): 111-120. Vidic Z et al. / OPRM1 related genetic variability and postoperative pain treatment in breast cancer 115 events were therefore evaluated in 99 patients. The vast majority of the patients who discontinued tramadol were from the higher dose group (P = 0.004). A total of 101 patients completed the follow- up visit one year after surgery and were included in the analysis of genetic factors associated with the chronic and neuropathic pain. Within the first four weeks of tramadol/paracet- amol treatment, the severity of the self-perceived acute pain assessed with the VAS scale was not as- sociated with the patient’s genotypes for any of the investigated polymorphisms in none of the time points (all P > 0.05) (Supplementary Table 1). Several patients experienced the side effects that could be related to tramadol treatment at least once within the first four weeks: 36 (36.7%) pa- tients experienced nausea, 9 (9.1%) patients expe- rienced vomiting, 35 (35.4%) patients experienced dizziness, and 48 (48.5%) patients experienced con- stipation. TABLE 2. The investigated polymorphism’s characteristics and frequencies Gene SNP Genotype N (%) PAF (%) MAF HapMap CEU expected (%) PHWE OPRM1 rs1799971 AA 84 (74.3) 14.2 15.6–16.7 0.570 AG 26 (23.0) GG 3 (2.7) rs677830 CC 56 (49.6) 27.4 20.7 0.098 CT 52 (46.0) TT 5 (4.4) MIR23B rs1011784* CC 63 (56.3) [1] 26.8 23.3 0.153 CG 38 (33.9) GG 11 (9.8) MIR107 rs2296616* GG 21 (18.6) 57.1 54.2–55.3 0.944 GA 55 (48.7) AA 37 (32.7) ASA = American Society of Anaesthesiology; CEU = Northern Europeans from Utah; HGVS = Human Genome Variation Society; HWE = Hardy-Weinberg equilibrium; N = sample size; PAF = polymorphic allele frequency; SNP = single nucleotide polymorphism; *KASP assays were designed on the reverse strand TABLE 3. The impact of investigated polymorphisms on constipation anytime during the first four weeks of tramadol treatment (N = 99) SNP Genotype Constipation anytime N (%) OR (95% CI) P OR (95% CI)adj Padj OPRM1 rs1799971 AA 30 (40) Ref. Ref. AG+GG 18 (75) 4.5 (1.6–12.64) 0.004 4.31 (1.52–12.17) 0.006 OPRM1 rs677830 CC 24 (48) Ref. Ref. CT+TT 24 (49) 1.04 (0.47–2.29) 0.922 0.98 (0.44–2.19) 0.964 MIR23B rs1011784 CC 29 (50) Ref. Ref. CG 16 (50) 1 (0.42–2.37) 1.000 0.96 (0.4–2.31) 0.930 GG 3 (37.5) 0.6 (0.13–2.75) 0.510 0.46 (0.1–2.23) 0.338 CG+GG 19 (47.5) 0.9 (0.4–2.03) 0.808 0.84 (0.37–1.91) 0.676 MIR107 rs2296616 GG 11 (57.9) Ref. Ref. GA 23 (48.9) 0.7 (0.24–2.04) 0.511 0.73 (0.25–2.16) 0.566 AA 14 (42.4) 0.54 (0.17–1.68) 0.285 0.53 (0.17–1.67) 0.276 GA+AA 37 (46.3) 0.63 (0.23–1.72) 0.364 0.64 (0.23–1.77) 0.386 adj = adjustment for tramadol dose; N = sample size; OR = odds ratio; SNP = single nucleotide polymorphism; 95% CI = 95% confidence interval Radiol Oncol 2023; 57(1): 111-120. Vidic Z et al. / OPRM1 related genetic variability and postoperative pain treatment in breast cancer116 Carriers of at least one polymorphic OPRM1 rs1799971 allele had a higher risk of constipation in the first four weeks compared to carriers of two wild-type alleles (OR = 4.5, 95% CI = 1.6–12.64, P = 0.004). This association remained significant after the adjustment for the tramadol dose (OR = 4.31, 95% CI = 1.52–12.17, P = 0.006). None of the other polymorphisms were associated with the overall risk for constipation during the first month after surgery (Table 3). Data for constipation for each week separately are shown in Supplementary Table 2. Carriers of at least one polymorphic OPRM1 rs677830 allele had a higher risk of con- stipation after 21 days of tramadol treatment when compared to carriers of two wild-type alleles (OR = 3.11, 95% CI = 1.08–8.89, P = 0.035). The risk of nausea after 28 days of tramadol treatment was significantly higher in carriers of two polymorphic MIR23B rs1011784 alleles com- pared to carriers of two wild-type alleles (OR = 7.35, 95% CI = 1.27–42.6, P = 0.026). Heterozygotes for MIR107 rs2296616 allele had a lower risk of nausea after the third week of tramadol treatment compared to carriers of two wild-type alleles (OR = 0.21, 95% CI = 0.05–0.87, P = 0.031). Similarly, car- riers of at least one polymorphic MIR107 rs2296616 had a lower risk of nausea after the third week of tramadol treatment compared to carriers of two wild-type alleles (OR = 0.30, 95% CI = 0.09–0.97, P = 0.045) (Table 4). None of the investigated pol- ymorphisms were associated with the risk for nausea within the first two weeks after surgery (Supplementary Table 3). One year after surgery 21 (20.8%) patients expe- rienced chronic pain and 25 (24.8%) experienced neuropathic pain. In carriers of two polymorphic MIR107 rs2296616 alleles, chronic pain was signifi- cantly more common compared to carriers of two wild-type alleles (35.3% compared to 0% of patients, P = 0.004). Carriers of at least one polymorphic OPRM1 rs677830 allele experienced less neuro- pathic pain compared to carriers of two wild-type alleles (OR = 0.38, 95% CI = 0.15–0.99, P = 0.047), but the difference was no longer significant after ad- justment for tramadol dose (P = 0.060). Carriers of at least one polymorphic MIR23B rs1011784 allele experienced more neuropathic pain compared to carriers of two wild-type alleles, but the difference was only significant after adjustment for tramadol dose (OR = 2.85, 95% CI = 1.07–7.59, P = 0.036). The other investigated miRNA polymorphism was not associated with the persistence of chronic or neu- ropathic pain (Table 5). Discussion Our study investigated the association of genetic variability of OPRM1 and genes coding for miR- NAs regulating OPRM1 expression with acute and long-term pain management as well as adverse ef- fects of tramadol treatment after surgical treatment of breast cancer and axillary lymphadenectomy. None of the investigated polymorphisms were associated with the intensity of acute pain after the surgery. However, we confirmed the associa- tion between some of the investigated polymor- phisms and the presence of adverse effects as well as chronic and neuropathic pain. In particular, OPRM1 rs1799971 polymorphism increased the risk of constipation in the first month of tramadol treatment, while OPRM1 rs677830 polymorphism TABLE 4. The impact of investigated miRNA polymorphisms on nausea after 21 and 28 days of tramadol treatment (N = 99) SNP Genotype Nausea 21 days N (%) OR (95% CI) P Nausea 28 days N (%) OR (95% CI) P MIR23B rs1011784 CC 9 (16.4) Ref. 4 (7.5) Ref. CG 4 (12.9) 0.76 (0.21–2.7) 0.668 5 (16.1) 2.36 (0.58–9.54) 0.230 GG 2 (25) 1.7 (0.3–9.83) 0.551 3 (37.5) 7.35 (1.27–42.6) 0.026 CG+GG 6 (15.4) 0.93 (0.3–2.86) 0.898 8 (20.5) 3.16 (0.88–11.39) 0.078 MIR107 rs2296616 GG 6 (31.6) Ref. 2 (10.5) Ref. GA 4 (8.9) 0.21 (0.05–0.87) 0.031 4 (8.7) 0.81 (0.14–4.84) 0.817 AA 5 (16.7) 0.43 (0.11–1.69) 0.229 6 (21.4) 2.32 (0.41–12.96) 0.338 GA+AA 9 (12) 0.30 (0.09–0.97) 0.045 10 (13.5) 1.33 (0.27–6.64) 0.730 N = sample size; OR = odds ratio; SNP = single nucleotide polymorphism; 95% CI = 95% confidence interval Radiol Oncol 2023; 57(1): 111-120. Vidic Z et al. / OPRM1 related genetic variability and postoperative pain treatment in breast cancer 117 increased the risk of constipation in the third week of tramadol treatment. OPRM1 rs677830 polymor- phism also reduced the risk of neuropathic pain one year after the surgery. The presence of MIR23B rs1011784 polymorphism increased the risk of nau- sea in the fourth week of tramadol treatment and increased the risk of neuropathic pain one year after the surgery. Lastly, the presence of MIR107 rs2296616 polymorphism reduced the risk of nau- sea in the third week of treatment and increased the risk of chronic pain one year after the surgery. So far, many studies confirmed the impact of OPRM1 rs1799971 polymorphism on pain per- ception, opioid response, the presence of adverse effects, and susceptibility to alcohol or drug de- pendence, but the majority of studies of OPRM1 rs1799971 polymorphisms were conducted on Asian population. According to systematic review and metaanalysis, carriers of at least one polymor- phic OPRM1 rs1799971 allele have higher opioid dose requirements to manage postoperative pain.26 However, after adjustment for different ethnic groups and different opioids, this effect remained significant only for the Asian population and in the group receiving morphine. In the Caucasian population, the association had not been con- firmed. The different ethnic origin of patients is, according to the authors of the review, one of the TABLE 5. The impact of investigated polymorphisms on chronic and neuropathic pain (N = 101) SNP Genotype Chronic painN (%) OR (95% CI) P OR (95% CI)adj Padj OPRM1 rs1799971 AA 15 (20.3) Ref. Ref. AG+GG 6 (22.2) 1.12 (0.39–3.28) 0.831 1.2 (0.4–3.57) 0.739 OPRM1 rs677830 CC 14 (27.5) Ref. Ref. CT+TT 7 (14) 0.43 (0.16–1.18) 0.101 0.44 (0.16–1.21) 0.112 MIR23B rs1011784 CC 9 (15.3) Ref. Ref. CG 10 (32.3) 2.65 (0.94–7.45) 0.065 2.85 (0.99–8.19) 0.052 GG 2 (20) 1.39 (0.25–7.64) 0.706 1.68 (0.29–9.83) 0.563 CG+GG 12 (29.3) 2.3 (0.86–6.11) 0.095 2.58 (0.94–7.1) 0.067 MIR107 rs2296616 GG 0 (0) Ref. Ref. GA 9 (18.4) / 0.099* AA 12 (35.3) / 0.004* GA+AA 21 (25.3) / 0.021* SNP Genotype Neuropathic pain N (%) OR (95% CI) P OR (95% CI)adj Padj OPRM1 rs1799971 AA 19 (25.7) Ref. Ref. AG+GG 6 (22.2) 0.83 (0.29–2.36) 0.722 0.94 (0.32–2.75) 0.915 OPRM1 rs677830 CC 17 (33.3) Ref. Ref. CT+TT 8 (16) 0.38 (0.15–0.99) 0.047 0.4 (0.15–1.04) 0.060 MIR23B rs1011784 CC 11 (18.6) Ref. Ref. CG 12 (38.7) 2.76 (1.04–7.31) 0.042 3.25 (1.17–9.02) 0.023 GG 2 (20) 1.09 (0.2–5.87) 0.919 1.59 (0.27–9.24) 0.607 CG+GG 14 (34.1) 2.26 (0.9–5.68) 0.082 2.85 (1.07–7.59) 0.036 MIR107 rs2296616 GG 3 (16.7) Ref. Ref. GA 11 (22.4) 1.45 (0.35–5.93) 0.607 1.37 (0.33–5.69) 0.666 AA 11 (32.4) 2.39 (0.57–10.02) 0.233 2.34 (0.55–9.97) 0.249 GA+AA 22 (26.5) 1.8 (0.48–6.83) 0.386 1.73 (0.45–6.65) 0.424 adj = adjustment for tramadol dose, N = sample size, OR = odds ratio, SNP = single nucleotide polymorphism, 95% CI = 95% confidence interval; *calculated using Fisher’s exact test Radiol Oncol 2023; 57(1): 111-120. Vidic Z et al. / OPRM1 related genetic variability and postoperative pain treatment in breast cancer118 main reasons for mentioned differences in opioid response among different populations, since MAF for polymorphic OPRM1 rs1799971 allele in the Caucasian population is lower compared to the Asian population, and thus limiting the recogni- tion of the recessive effect of the polymorphism. Besides, it is possible that other gene variants with an impact on MOR activity, that are in linkage disequilibrium with OPRM1 rs1799971 polymor- phism, are the reason for differences in opioid re- sponse.26 Other authors also state that ethnic ori- gin is an important cause for conflicting research results on the impact of OPRM1 rs1799971 poly- morphism on subjects’ response to opioid drugs.4 According to the 1000Genome project, MAF in the Asian population is between 39 and 42%, while MAF in the European population is 16%.27 In our group of patients, MAF for OPRM1 rs1799971 was 14.2%, which coincides with the expected fre- quency for Europeans. Another study conducted on the Caucasian population, investigating the impact of OPRM1 and COMT polymorphisms on postoperative acute and chronic pain could not confirm the impact of OPRM1 rs1799971 polymor- phism on any of these types of pain28, which is consistent with the results of our study. The com- bination of tramadol and paracetamol was more effective for the treatment of neuropathic pain in wild-type homozygotes compared to carriers of OPRM1 rs1799971 polymorphic allele in a group of the Asian patients with oxaliplatin-induced neuropathy.8 Furthermore, wild-type homozy- gotes had lower opioid dose requirements for the treatment of chronic pain compared to carriers of OPRM1 rs1799971 polymorphic allele in European patients.29 Adverse effects, especially nausea and gastro- intestinal events, were more common in a group of people with wild-type genotype compared to the carriers of polymorphic OPRM1 rs1799971 al- lele.7,30 A possible reason for this could be a loss of the N-glycosylation site of MOR in the carriers of polymorphic allele29, since the N-glycosylation site of MOR may be involved in the trafficking into the cell membrane, binding of ligands, and signal transduction.31 On the other hand, OPRM1 rs1799971 polymorphism could impact the expres- sion levels of MOR directly and consequently re- duce the risk of opioid toxicity.29 Contrary to ex- pectations, our results showed an increased risk of constipation in the carriers of the polymorphic OPRM1 rs1799971 allele. Since the expression of MOR is tissue-specific, the impact on constipation cannot be explained by the central action of opi- oids. Instead, we should investigate the expression patterns and mechanisms of action of MOR on the periphery. A study of the association between OPRM1 rs677830 polymorphism and postoperative pain treatment with morphine in the Caucasian popu- lation showed no significant influence of polymor- phism, although an impact of the haplotype of seven polymorphisms of the OPRM1 gene, includ- ing rs1799971 and rs677830, on morphine require- ment has been observed.12 Due to the presence of a stop codon that leads to reduced expression of MOR caused by OPRM1 rs677830 polymorphism32, it was expected that greater severity of acute pain will be reported from the carriers of at least one polymorphic OPRM1 rs677830 allele. As the great- er severity of acute pain is one of the main risk factors for the presence of persistent pain33, we expected increased risk of chronic or neuropathic pain in carriers of at least one polymorphic al- lele, yet our results showed no impact on severity of acute pain and even indicated on reduced risk of neuropathic pain in carriers of polymorphic rs677830 allele. A literature search showed no re- port on the impact of mentioned polymorphism on adverse effects after opioid pain treatment or the presence of chronic or neuropathic pain so far. A study conducted on the mouse and human neuronal cells showed that long-term morphine treatment cannot influence the transcription of OPRM1. On the other hand, it can lead to increased miR-23b levels, which can bind to mRNA for MOR1 and thus prevent the translation of mRNA to the receptor, which causes a drug tolerance.17,34 Tramadol and morphine have a similar molecular structure, thus there is a possibility that MOR ex- pression may be affected by tramadol in the same way. An altered sequence of miR-23b, caused by MIR23B rs1011784 polymorphism, could change its target sequence and therefore prevent binding of miR-23b to mRNA for MOR1. In that case, recep- tor activity would remain unchanged, but we were unable to confirm these assumptions. Similar to miR-23b, long-term morphine expo- sure led to up-regulated miR-107 levels, leading to decreased levels of MOR1A in human neuro- blastoma cells and striatum of morphine-tolerant mouse.15 It would be interesting to evaluate the possible impact of tramadol on miR-107 expression as well. In addition, even though MIR107 rs2296616 polymorphism does not lead to decreased tran- scription of DNA to pre-miRNA, it could affect the processing of pre-miR-107 to mature transcript and consequently levels of miR-107.35 As a result, it Radiol Oncol 2023; 57(1): 111-120. Vidic Z et al. / OPRM1 related genetic variability and postoperative pain treatment in breast cancer 119 could affect MOR expression, but to confirm this we would have to do the quantification of miR-107 and MOR levels. Despite the confirmed association between polymorphisms in miRNA genes and tramadol treatment outcome, it is not sure that these miRNA acts through the altered activity of MOR. miR-23b played a crucial role in neuropathic pain relief in a mouse model after spinal cord injury. When a higher level of pain was present, decreased expres- sion level of miR-23b was measured and therefore increased levels of its target gene NOX4, coding for NADPH oxidase 4, that contributes to reac- tive oxygen species formation. After infusion of ectopic miR-23b molecules, an expression level of NOX4 decreased, and the symptoms improved.36 From the results of the mentioned study, we can conclude that miR-23b can influence the percep- tion of pain through its influence on various genes, not only OPRM1. Additionally, miR-107 paralogue miR-103 that differs in only one nucleotide in 3’-end, therefore regulating overlapping target molecules15, includ- ing mRNA for MOR in mice and humans, was shown to be regulating pain perception in rats and was down-regulated in neuropathic animals. It is responsible for the altered expression level of three subunits of Cav1.2 L-type calcium channels that play a crucial role in the sensation in chronic neuropathic pain.37 It is reasonable to assume that the miR-107 molecule could have the same effect. If polymorphism in MIR107 alters the target se- quence of a mentioned molecule, it would conse- quently lead to the same effect as downregulation of the miR-107, therefore increased neuropathic pain. Yet our results only suggested the impact of miR-107 on chronic pain perception. Our study was one of the few studies inspecting the impact of polymorphisms of the OPRM1 gene on the tramadol treatment outcome in Caucasians. Nevertheless, it has some limitations such as a rela- tively small sample size of the patients and that the genotyping analysis was performed retrospective- ly. Since only a few studies investigated the impact of miRNA on the expression and functionality of MOR, it was a challenge to narrow the selection of miRNA and potentially functional polymor- phisms in genes coding for miRNA. Furthermore, we investigated the impact of polymorphisms on pain, which is always liable to subjective assess- ment, even though we used VAS and other stand- ardized questionnaires to limit this impact. On the other hand, the advantage of our study was an ethnically homogenous group of patients, as well as the unified treatment and follow-up protocol of patients. Overall, it was a longitudinal, prospec- tive, randomized double-blind clinical trial, where neither the healthcare professionals nor the pa- tients knew the dose level of tramadol. Conclusions In this study, we observed for the first time to our knowledge, that the presence of OPRM1 rs677830 polymorphism reduces the risk for the presence of neuropathic pain and increases the risk of con- stipation in response to tramadol pain treatment. Furthermore, we observed for the first time the association of investigated polymorphisms in miR-23b and miR-107 coding genes with tramadol treatment outcome. The results of our study are expanding the knowledge in the field of person- alized medicine that could lead to improved pain management and reduced risk of adverse effects, therefore improving the quality of patient’s life.38 Acknowledgments This work was financially supported by the Slovenian Research Agency (ARRS Grants No. P1- 0170 and P3-0289). References 1. Subedi M, Bajaj S, Kumar MS, Yc M. An overview of tramadol and its usage in pain management and future perspective. Biomed Pharmacother 2019; 111: 443-51. doi: 10.1016/j.biopha.2018.12.085 2. Besic N, Smrekar J, Strazisar B. Chronic adverse effects after an axillary lymphadenectomy in breast cancer patients after administering weaker and stronger postoperative analgesia: results of a prospective double-blind randomized study. Breast Cancer Res Treat 2020; 182: 655-63. doi: 10.1007/ s10549-020-05713-3 3. World Health Organisation. Tramadol, update review report. [Internet]. 2014. p. 1-39. [cited 2022 Aug 14]. Available at: http://www.who.int/medi- cines/areas/quality_safety/6_1_Update.pdf 4. Crist RC, Berrettini WH. Pharmacogenetics of OPRM1. Pharmacol Biochem Behav 2014; 123: 25-33. doi: 10.1016/j.pbb.2013.10.018 5. Wang S. Historical review: opiate addiction and opioid receptors. Cell Transplant 2019; 28: 233-8. doi: 10.1177/0963689718811060 6. Yoshida K, Nishizawa D, Ide S, Ichinohe T, Fukuda KI, Ikeda K. A pharmaco- genetics approach to pain management. Neuropsychopharmacol Rep 2018; 38: 2-8. doi: 10.1002/npr2.12003 7. Muriel J, Margarit C, Barrachina J, Ballester P, Flor A, Morales D, et al. Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients. Basic Clin Pharmacol Toxicol 2019; 124: 439-48. doi: 10.1111/bcpt.13155 8. Liu YC, Wang WS. Human mu-opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ul- tracet) in oxaliplatin-induced painful neuropathy. Cancer 2012; 118: 1718- 25. doi: 10.1002/cncr.26430 Radiol Oncol 2023; 57(1): 111-120. Vidic Z et al. / OPRM1 related genetic variability and postoperative pain treatment in breast cancer120 9. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008; 83: 559-66. doi: 10.1038/sj.clpt.6100385 10. Lötsch J, von Hentig N, Freynhagen R, Griessinger N, Zimmermann M, Doehring A, et al. Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics 2009; 19: 429-36. doi: 10.1097/ fpc.0b013e32832b89da 11. Klepstad P, Rakvåg TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004; 48: 1232-9. doi: 10.1111/j.1399- 6576.2004.00517.x 12. De Gregori M, Diatchenko L, Ingelmo PM, Napolioni V, Klepstad P, Belfer I, et al. Human genetic variability contributes to postoperative morphine consumption. J Pain 2016; 17: 628-36. doi: 10.1016/j.jpain.2016.02.003 13. Riffo-Campos ÁL, Riquelme I, Brebi-Mieville P. Tools for sequence-based miRNA target prediction: what to choose? Int J Mol Sci 2016; 17: 1987. doi: 10.3390/ijms17121987 14. Xu W, San Lucas A, Wang Z, Liu Y. Identifying microRNA tar- gets in different gene regions. BMC Bioinformatics 2014; 15: S4. doi: 10.1186/1471-2105-15-S7-S4 15. Lu Z, Xu J, Xu M, Pasternak GW, Pan YX. Morphine regulates expression of μ-opioid receptor MOR-1A, an intron-retention carboxyl terminal splice variant of the μ-opioid receptor (OPRM1) gene via miR-103/miR-107. Mol Pharmacol 2014; 85: 368-80. doi: 10.1124/mol.113.089292 16. Zheng H, Law PY, Loh HH. Non-coding RNAs regulating morphine function: with emphasis on the in vivo and in vitro functions of miR-190. Front Genet 2012; 3: 113. doi: 10.3389/fgene.2012.00113 17. Wu Q, Law PY, Wei LN, Loh HH. Post-transcriptional regulation of mouse mu opioid receptor (MOR1) via its 3’ untranslated region: a role for micro- RNA23b. FASEB J 2008; 22: 4085-95. doi: 10.1096/fj.08-108175 18. Rodríguez RE. Morphine and microRNA activity: is there a relation with ad- diction? Front Genet 2012; 3: 223. doi: 10.3389/fgene.2012.00223 19. Besic N, Smrekar J, Strazisar B. Acute pain and side effects after tramadol in breast cancer patients: results of a prospective double-blind randomized study. Sci Rep 2020; 10: 18766. doi: 10.1038/s41598-020-75961-2 20. Fitz-Henry J. The ASA classification and peri-operative risk. Ann R Coll Surg Engl 2011; 93: 185-7. doi: 10.1308/rcsann.2011.93.3.185a 21. Cariaso M, Lennon G. SNPedia: a wiki supporting personal genome annota- tion, interpretation and analysis. Nucleic Acids Res 2012; 40: D1308-12. doi: 10.1093/nar/gkr798 22. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 2015; 31: 3555-7. doi: 10.1093/ bioinformatics/btv402 23. Huang H-Y, Lin Y-C-D, Li J, Huang K-Y, Shrestha S, Hong H-C, et al. miRTarBase 2020: updates to the experimentally validated microRNA–target interac- tion database. Nucleic Acids Research 2020; 48: D148-54. doi: 10.1093/ nar/gkz896 24. Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Research 2020; 48: D127-31, doi: 10.1093/ nar/gkz757 25. Chang L, Zhou G, Soufan O, Xia J. miRNet 2.0: network-based visual analytics for miRNA functional analysis and systems biology. Nucleic Acids Research 2020; 48: W244-51. 10.1093/nar/gkaa467 26. Hwang IC, Park JY, Myung SK, Ahn HY, Fukuda K, Liao Q. OPRM1 A118G gene variant and postoperative opioid requirement: a systematic re- view and meta-analysis. Anesthesiology 2014; 121: 825-34. doi: 10.1097/ ALN.0000000000000405 27. National Library of Medicine (US), National Center for Biotechnology Information. db SNP: rs1799971. [cited 2022 Oct 30]. Available at: https:// www.ncbi.nlm.nih.gov/snp/rs1799971 28. Matic M, de Hoogd S, de Wildt SN, Tibboel D, Knibbe CA, van Schaik RH. OPRM1 and COMT polymorphisms: implications on postoperative acute, chronic and experimental pain after cardiac surgery. Pharmacogenomics 2020; 21: 181-93. doi: 10.2217/pgs-2019-0141 29. Muriel J, Margarit C, Planelles B, Serralta MJ, Puga C, Inda MD, et al. OPRM1 influence on and effectiveness of an individualized treatment plan for pre- scription opioid use disorder patients. Ann N Y Acad Sci 2018; 1425: 82-93. doi: 10.1111/nyas.13735 30. The Pharmacogenomics Knowledge Base (PharmGKB). Variant annotations: rs1799971. [cited 2022 Oct 30]. Avalable at: https://www.pharmgkb.org/ variant/PA166156991/variantAnnotation 31. Kroslak T, Laforge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem 2007; 103: 77-87. doi: 10.1111/j.1471- 4159.2007.04738.x 32. National Library of Medicine (US), National Center for Biotechnology Information. db SNP: rs677830. [cited 2022 Oct 30]. Available at: https:// www.ncbi.nlm.nih.gov/snp/rs677830 33. Wang L, Guyatt GH, Kennedy SA, Romerosa B, Kwon HY, Kaushal A, et al. Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies. CMAJ 2016; 188: E352-61. doi: 10.1503/cmaj.151276 34. Wu Q, Zhang L, Law PY, Na Wei LN, Loh HH. Long-term morphine treatment decreases the association of μ-opioid receptor (MOR1) mRNA with poly- somes through miRNA23b. Mol Pharmacol 2009; 75: 744-50. doi: 10.1124/ mol.108.053462 35. Wang S, Lv C, Jin H, Xu M, Kang M, Chu H, et al. A common genetic varia- tion in the promoter of miR-107 is associated with gastric adenocarcinoma susceptibility and survival. Mutat Res 2014; 769: 35-41. doi: 10.1016/j. mrfmmm.2014.07.002 36. Im YB, Jee MK, Choi JI, Cho HT, Kwon OH, Kang SK. Molecular targeting of NOX4 for neuropathic pain after traumatic injury of the spinal cord. Cell Death Dis 2012; 3: e426. doi: 10.1038/cddis.2012.168 37. Favereaux A, Thoumine O, Bouali-Benazzouz R, Roques V, Papon MA, Salam SA, et al. Bidirectional integrative regulation of Cav1.2 calcium channel by microRNA miR-103: role in pain. EMBO J 2011; 3018: 3830-41. doi: 10.1038/ emboj.2011.249 38. Stamer UM, Zhang L, Stüber F. Personalized therapy in pain management: where do we stand? Pharmacogenomics 2010; 11: 843-64. doi: 10.2217/ pgs.10.47